Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (Split Virion),Inactivated
Sponsor: Changchun Institute of Biological Products Co., Ltd.
This PHASE4 trial investigates Enterovirus Infections and Influenza and is currently completed. Changchun Institute of Biological Products Co., Ltd. leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2022 — Nov 2022 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Mar 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
Status: Not Yet Recruiting → Active Not Recruiting
-
Oct 2019 — Oct 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changchun Institute of Biological Products Co., Ltd.
- China National Biotec Group Company Limited
- Guizhou Center for Disease Control and Prevention
- Henan Center for Disease Control and Prevention
- National Institutes for Food and Drug Control, China
- Peking University
- Wuhan Institute of Biological Products Co., Ltd
- Zhejiang Provincial Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .